Prevalence of the JAK2 V617F mutation associated with splanchnic vein thrombosis. A 10-year retrospective study

• References

• 1 Kiladjian JJ, Cervantes F, Leebeek FW. et al. The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. Blood 2008; 111: 4922-4929.
• 2 De Stefano V, Fiorini A, Rossi E. et al. Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders. J Thromb Haemost 2007; 5: 708-714.
• 3 Regina S, Herault O, D’Alteroche L. et al. JAK2 V617F is specifically associated with idiopathic splanchnic vein thrombosis. J Thromb Haemost 2007; 5: 859-861.
• 4 Colaizzo D, Amitrano L, Tiscia GL. et al. The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis. J Thromb Haemost 2007; 5: 55-61.
• 5 Patel RK, Lea NC, Heneghan MA. et al. Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome. Gastroenterology 2006; 130: 2031-2038.
• 6 Plume G, Vaya A, Ferrando F. et al. JAK2V617F mutation as a marker of a latent myeloproliferative disorder in a patient with Budd-Chiari syndrome and factor V Leiden mutation. Thromb Haemost 2007; 98: 681-682.
• 7 Murphy S. Diagnostic criteria and prognosis in polycythemia vera and essential thrombocythemia. Semin Hematol 1999; 36: 9-13.
• 8 Jaffe ES, Harris NL, Stein H. et al. World Health Organization Classification of Tumours. vol. 3. Pathology and genetics of Tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2001: 31-42.
• 9 James C, Delhommeau F, Marzac C. et al. Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis. Leukemia 2006; 20: 350-353.
• 10 Gruppo Italiano Studio Policitemia.. Polycythemia vera: the natural history of 1213 patients followed for 20 years. Ann Intern Med 1995; 123: 656-664.
• 11 Bousser MG, Ferro JM. Cerebral venous thrombosis: an update. Lancet Neurol 2007; 6: 162-170.
• 12 Bellucci S, Cassinat B, Bonnin N. et al. The V617F JAK 2 mutation is not a frequent event in patients with cerebral venous thrombosis without overt chronic myeloproliferative disorder. Thromb Haemost 2008; 99: 1119-1120.
• 13 Hermouet S, Dobo I, Lippert E. et al. Comparison of whole blood vs purified blood granulocytes for the detection and quantitation of JAK2(V617F). Leukemia 2007; 21: 1128-1130.
• 14 Larsen TS, Pallisgaard N, Moller MB. et al. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype. Eur J Haematol 2007; 79: 508-515.
• 15 Vannucchi AM, Antonioli E, Guglielmelli P. et al. Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood 2007; 110: 840-846.